|
Country
|
HBsAg
|
Anti-HCV
|
|---|
|
Year
|
Sample size
|
Prevalence (95% CI)
|
Study design
|
Setting
|
Year
|
Sample size
|
Prevalence (95% CI)
|
Study design
|
Setting
|
|---|
|
Austria
|
–
|
–
|
–
| | |
2013
|
48
|
31.3 (18.7–46.3)
|
DT
|
ODD
|
|
Croatia
|
2007
|
200
|
0.5 (0.0–2.8)
|
SP
|
PRI
|
2007
|
200
|
44 (37.0–51.2)
|
SP
|
PRI
|
|
Cyprus
|
2013
|
82
|
6.1 (2.0–13.7)
|
DT
|
DTC
|
2013
|
82
|
47.6 (36.4–58.9)
|
DT
|
DTC
|
|
Czech Republic
|
–
|
–
|
–
| | |
2013
|
1889
|
14.6 (13.1–16.3)
|
DT
|
NSP
|
|
Denmark
|
–
|
–
|
–
| | |
2008
|
223
|
52.5 (45.7–59.2)
|
SP (UAT)
|
ODD
|
|
Finland
|
–
|
–
|
–
| | |
2009
|
682
|
60.5 (56.8–64.3)
|
SP (UAT)
|
NSP
|
|
Greece
|
2013
|
1337
|
3.0 (2.2–4.1)
|
DT
|
DTC; LTS; OTH; PHL; PRI; STR;
|
2013
|
1309
|
68.1 (65.5–70.6)
|
DT
|
DTC; LTS; PHL; PRI; OTH STR;
|
|
Hungary
|
2011
|
664
|
0.5 (0.1–1.3)
|
SP
|
DTC, NSP
|
2011
|
652
|
24.1 (20.8–27.6)
|
SP
|
DTC; NSP
|
|
Ireland
|
2010
|
200
|
0.5 (0.0–2.8)
|
SP
|
PRI
|
2010
|
200
|
41.5 (34.6–48.7)
|
SP
|
PRI
|
|
Italy
|
–
|
–
|
–
| | |
2010
|
743
|
60.5 (56.8–64.0)
|
DT
|
DTC
|
|
Latvia
|
2013
|
562
|
2.1 (1.1–3.7)
|
DT
|
DTC
|
2013
|
522
|
70.1 (66.0–74.0)
|
DT
|
NSP
|
|
Malta
|
–
|
–
|
–
| | |
2013
|
109
|
13.8 (7.9–21.7)
|
DT
|
ANT; DTC; HTC; OHC; PHL; STI
|
|
Norway
|
–
| |
–
| | |
2013
|
6342
|
63.0 (61.8–64.2)
|
SP
|
DTC
|
|
Portugal
|
2013
|
399
|
6.3 (4.1–9.1)
|
DT
|
DTC
|
2013
|
414
|
84.3 (80.4–87.7)
|
DT
|
DTC
|
|
Slovenia
|
–
|
–
|
–
| | |
2009
|
112
|
32.1 (23.6–41.6)
|
DT
|
DTC
|
|
United Kingdom
|
–
|
–
|
–
| | |
2013
|
3144
|
49.1 (47.4–50.9)
|
SP (UAT)
|
DTC; LTS; OTH; NSP
|
- Acronyms (study design): DT diagnostic testing, SP specific prevalence study, UAT unlinked anonymous testing
- Acronyms (setting): ANT Antenatal Clinics, DTC Drug Treatment Centres, HTC HIV Testing Centres, LTS Low Threshold Services, ODD Overdose Deaths, OHC Other Hospitals or Clinics, OTH Other, NSP Needle Exchange Programmes, PHL Public Health Laboratories, PRI Prisons, STI STI clinics, STR Street
